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Abstract: Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia 
together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general 
results from an insulin availability and need imbalance. In a great number of patients, marketed 
anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, 
thus being associated with severe adverse effects and leading to an emerging interest in natural 
compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich 
compounds) as a novel approach for prevention, management and/or treatment of either non-
insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this 
review, some of these promising glucose-lowering agents will be comprehensively discussed. 
Keywords: diabetes mellitus; metabolic syndrome; glucose-lowering agents; sugar-lowering oils; 
phytotherapy 
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1. Introduction 
Diabetes mellitus (DM) remains as one of the major global epidemics of the 21st century. The 
name of this disease is derived from a Greek word meaning “going through” and a Latin word for 
“honey” or “sweet”[1] and is characterized by the production of a large amount of urine with a 
honey-like taste [2]. DM is a metabolic disorder characterized by chronic hyperglycemia together 
with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from 
an insulin availability and need imbalance [1,3–5]. Nowadays, the number of people suffering from 
DM and its complications is increasing, in part due to the current worldwide lifestyle: Sedentary 
lifestyle, high-fat diet, obesity and longer life span [6]. DM has become a global health problem since 
it is the most common clinical disorder, affecting nearly 10% of the population all over the world and 
constantly increasing day by day [7]. In 2015, 246 million people were estimated to have DM 
worldwide, among which about 80% resided in developing countries [7]. It was reported by World 
Health Organization (WHO) that about 1.1 million people died of diabetic complications, and it is 
expected that the death rate will increase up to 50% in 2030 [7]. The disease has multiple etiologies 
and results, briefly, from the impaired release of insulin by the pancreatic β-cells with absolute or 
relative insulin deficiency in plasma. Moreover, the pathophysiology of DM is also characterized by 
inadequate or defective insulin receptors activity, insulin-resistance characterized by an insufficient 
response of peripheral tissues to insulin, along with the production of inactive insulin and/or early 
destruction of insulin, before its action has been carried out in tissues [1,7]. As an integrated part of a 
metabolic syndrome, DM is a global disease with great influence on human health and mortality, 
particularly regarding cardiovascular disorders. Indeed, it is well-established that patients with DM 
also suffer from dyslipidemia and have an increased risk of coronary heart disease, as well as 
peripheral vascular disease and cerebrovascular disease. All together, these facts demand the control 
of both the blood glucose and lipid levels [7] in order to avoid the serious complications related to 
the disease, such as heart and blood vessel diseases [7]. 
DM can be manifested as type 1, also named insulin-dependent DM (T1DM or IDDM), or type 
2, also called non-insulin-dependent DM (T2DM or NIDDM) [7,8]. T1DM represents about 10% of 
the DM cases in United States and Europe and results from the destruction of insulin-secreting 
pancreatic β-cells by an autoimmune-mediated process that may, under certain circumstances, have 
been triggered by a viral infection[3,4,8]. The pancreatic islets are infiltrated by T-lymphocytes and 
the autoantibodies islet cell antibodies (ICA), and insulin autoantibodies (IAA) can be detected. 
T1DM is subdivided in two types: T1A, also known as immune-mediated or juvenile DM is the most 
common form (occurs in 95% of T1DM patients) and is more prevalent among young people; and 
T1B or idiopathic. T1A results from the pancreatic β-cells destruction, leading to an absolute insulin 
deficiency, hyperglycemia and an increased breakdown of body fats and proteins. Consequently, 
these patients are typically lean individuals and suffer from ketoacidosis, since lipolysis is not 
inhibited by insulin and the free fatty acids are released from adipocytes and converted into ketones 
in the liver. On the other hand, idiopathic DM, is a strongly inherited DM in which there is no 
evidence of an autoimmune-mediated pancreatic β-cells destruction; patients suffer from recurrent 
ketoacidosis episodes that result from the varying degrees of insulinemia with transitory periods of 
absolute insulin deficiency[1]. T1DM occurs more frequently in the carriers of HLA-DR3 and HLA-
DR4 genes, suggesting a genetic disposition for the disease [8]. 
T2DM is the most common presentation of DM and the fourth leading cause of death in 
industrialized countries, affecting over 5% of the world’s population and 1/4 of the elderly [8]. T2DM 
is a chronic metabolic disorder with a progressive worsening of both carbohydrate and lipid 
metabolism profiles. It is a heterogeneous condition characterized by a hyperglycemia status, mainly 
due to peripheral insulin resistance and enhanced hepatic glucose production, associated with a 
relative insulin deficiency. In fact, these patients can present higher, normal or low insulin levels 
resulting from an impaired β-cell function and insulin secretion [8–10]. Although T2DM is a 
metabolic disorder resulting from both β-cell dysfunction (with altered insulin levels) and impaired 
insulin action (insulin resistance), there is no evidence of human leukocyte antigen (HLA) markers 
or autoantibodies activity [4]. At a cellular level, the overproduction of glucose by the liver 
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significantly leads to fasting hyperglycemia as a direct result of the increase in the excess circulating 
free fatty acids (FFA) being oxidized after the release from the adipocyte [8]. 
β-Cell dysfunction results from the (i) decreased β-cell mass, increased β-cell apoptosis or 
decreased regeneration, (ii) long-standing insulin resistance leading to β-cell exhaustion, (iii) 
glucotoxicity-inductor chronic hyperglycemia, and (iv) chronic elevation of FFA, inducing 
lipotoxicity and amyloid deposition in β-cells[1]. Relative insulin deficiency can also be caused by 
autoantibodies against insulin receptors or insulin itself, or by rare defects in the biosynthesis of 
insulin, insulin receptors, or intracellular transmission [11–13]. The following etiological factors 
should also be considered: (i) pancreatitis, which destroys pancreatic β-cells and leads to 
pancreatectomy, (ii) increased release of insulin antagonistic hormones, such as somatotropin, 
glucocorticoids, epinephrine, progestogens, choriomammotropin, ACTH, thyroid hormone and 
glucagon, and (iii) mitochondrial dysfunction (mitochondrial loss and increased production of 
oxidants that promote insulin resistance), since this organelle is the main source of energy to cells 
and thus crucial to many cellular functions, including ATP production, biosynthesis of amino-acids 
and lipids, cytosolic calcium transport and apoptotic stimuli control. Muscle-biopsy studies 
performed in T2DM patients revealed mitochondrial dysfunction and a reduced expression of 
peroxisome proliferator-activated receptor gamma coactivator 1 (PGC1α), which is an essential 
regulator of mitochondrial biogenesis and function since it interacts with co-activating transcription 
factors (namely, nuclear respiratory factors, peroxisome proliferator-activated receptors (PPARs), 
thyroid hormone and also glucocorticoid and estrogen-related α- and γ-receptors). Thus, we may 
consider PGC1α-regulated mitochondrial biogenesis as a possible future therapeutic target for the 
prevention of the mitochondrial dysfunction in diabetic patients [14]. 
Despite the increasing prevalence in obese adolescents, the majority of the patients belong to 
elderly populations and are overweight. Obesity is indeed considered a major risk factor and an 
important trigger for the disease [6]. Resulting from the combination of three main factors – genetic 
disposition, large food intake and physical inactivity—obesity leads to an imbalance between the 
energy supply and expenditure, increasing free fatty acids in the blood and in turn reducing glucose 
utilization in muscle and fatty tissues, finally contributing to insulin resistance and an increase of 
insulin release, further raised by the resulting down-regulation of the insulin receptors. 
Unfortunately, only less than one-half of the diabetic patients receive treatment and even less of these 
achieve glycemia levels that avoid the disease associated morbidity, thus contributing to the 
development of severe long-term complications at macrovascular (coronary artery disease and 
stroke) and microvascular (retinopathy, neuropathy, nephropathy and other microangiopathies) 
levels, which may have an acute or chronic character [1,8]. 
In fact, despite being known for decades, the cure of DM is currently an unmet clinical need. 
Prophylactic treatment is available and while T1DM patients require an external insulin supply since 
the diagnosis, initial therapy for newly diagnosed T2DM patients is conventionally an adequate diet 
and exercise as they lead to a marginal improvement in insulin sensitivity and a corresponding 
reduction in hyperglycemia [1,8]. Nevertheless, disease progression and patient non-adherence 
usually culminates in treatment failure within a few months and an oral antidiabetic agent is hence 
prescribed. Despite the great variety of therapeutic options available for hyperglycemic management 
in T2DM patients, including some combinations of these, they are not recognized as adequately 
effective in maintaining a long-term glycemic control in most patients [8,9]. Furthermore, most 
marketed agents are associated with some adverse events, such as hypoglycemia and/or involuntary 
body weight gain, that often hamper the treatment adherence. A medical need for improving 
pharmacological therapy of T2DM remains therefore a great need [9]. The research for new glucose-
lowering drugs having minimal or no side effects and extracted from medicinal plants is a current 
challenge for several research groups worldwide. 
There has been an increasing interest in natural compounds, especially those derived from 
plants, as a novel therapeutic approach to prevent, manage and/or treat T2DM and MS. In this review, 
novel natural sugar lowering compounds and herbal extracts currently under investigation for use 
in the treatment of T2DM will be discussed, considering in vitro and in vivo evidence. A special 
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emphasis has been placed on flavonoids, naturally occurring phenolic compounds with a broad range 
of biological activities and whose biological effects have been increasingly studied in relation to DM. 
In turn, natural compounds that may be promising in the management of obesity, insulin resistance 
and MS, such as β-tigogenin cellobioside (tiqueside), S. japonica L or water-soluble chitosan, can also 
play an essential role in T2DM treatment. Despite the promising results, further research is required, 
specially focusing on toxicity, efficacy and safety studies and mechanisms of pharmacological action. 
The several essential oils that have demonstrated their sugar lowering capacity will be discussed in 
this paper. 
2. Pathophysiology of T2DM 
DM is a complex metabolic disorder with an inherent increased risk of both micro- and 
macrovascular disease; its main clinical characteristic is hyperglycemia [15]. In the absence of 
adequate interventions, the Metabolic Syndrome (MS), also called syndrome X or insulin-resistance 
syndrome, may lead to insulin-resistant-T2DM and related cardiovascular complications such as 
coronary heart disease or stroke and non-vascular pathologies such as cancer, infections, liver 
diseases and mental and nervous systems disorders [15]. In fact, cardiovascular diseases constitute 
the main cause of mortality among T2DM patients [16]. It is a dysfunction of the human metabolism 
essentially characterized by glucose intolerance and/or insulin resistance, hypertension, dyslipidemia 
and/or obesity. 
To better understand the pathophysiology of DM, carbohydrates, lipid metabolism and their 
regulation, should be investigated. The main characteristics of pancreatic function in healthy 
individuals versus in diabetic individuals are summarized in Figure 1. 
Glucose is the main substrate for energetic metabolism [17–20]. Narrow levels of plasma glucose 
must be maintained, by means of glucose sequestration, synthesis and consumption, being brain and 
erythrocytes fully glucose-dependent. Six main metabolic processes are tightly regulated in order to 
maintain glucose homeostasis: (i) glycolysis—glucose is converted to lactate, in erythrocytes, renal 
medulla and skeletal muscle (in the absence of oxygen) and in central nervous system, heart, skeletal 
muscle (requiring oxygen consumption), (ii) glycogenesis —glycogen is synthetized from glucose in 
liver and muscle, contributing to glucose storage, (iii) glycogenolysis—glucose is obtained from 
stored-glycogen breakdown, (iv) gluconeogenesis—glucose is produced in liver and renal cortex 
from amino acids, lactate and glycerol resulted from lipolysis, (v) lipolysis—glycerol and free fatty 
acid are obtained from triacylglycerols breakdown, and (vi) lipogenesis—fat is storage in form of 
triacylglycerols synthetized from free fatty acids and glycerol. 
Maillard reaction products, known as advanced glycated end-products (AGEs) and as advanced 
lipoperoxydation end-products (ALEs), show increasing concentrations in tissue as age increases, 
accelerating the pathogenesis of several diabetes mellitus complications, namely, diabetic 
nephropathy [21]. There is an increase in lipid peroxidation and AGE/ALE compound formation in 
diabetic individuals, either in plasma or body tissues, most probably because they suffer a metabolic 
process upon both elevated glucose levels and oxidative stress status, which simulate a mechanistic 
connection among dyslipidemia and DM complications [22]. 
These facts corroborate the great need for compounds that are able to prevent the AGE/ALE 
formation; some of those already known (some angiotensin-converting enzyme inhibitors, 
angiotensin II type-1 receptor blockers, metformin, aminoguanidine, pyridoxamine, OPB-9195 and 
carnosine) and others that remain under research, such as LR-9 and LR-74, which have been studied 
in streptozotocin (STZ)-induced diabetic rat models for both premature kidney disease and 
dyslipidemia [21,23]. After 32 weeks of treatment, although no effect on elevated blood glucose levels 
was reported, there was a significant inhibition of the albuminuria, both plasma creatinine and lipid 
peroxidation and also hyperlipidemia; furthermore, the Nε-(carboxymethyl)lysine (CML)-AGE 
accumulated in the renal glomerular apparatus and tubules decreased, as well as the AGE-linked 
fluorescence and cross-linking of tail collagen and finally the CML and Nɛ-(carboxyethyl)-lysine 
(CEL) identified in skin collagen [24]. All these findings indicate that AGE/ALE inhibitors may be a 
good approach to retard kidney disease progression and, in parallel, prevent alterations in lipid 
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metabolism in diabetic rat models. Finally, researchers found that these compounds may have a 
protective antioxidant action by inhibition of the lipid peroxidation reaction, thus providing an 
alternative therapeutic option to treat some diabetic macrovascular complications [22]. 
Several food constituents, namely, those salty, enriched with protein, having baking powder, 
distinct sugars and oils from a plant raw material or even grape derivatives, were analyzed for AGE 
inhibitor activity and it was found that (i) by using glucose as sugar, higher concentrations of CML 
were achieved compared to white beet sugar; (ii) refined sucrose registered much lower CML values 
than raw cane sugar; and (iii) the CML that is produced highly depends on the unsaturation degree 
of the oils, though other oil constituents (such as phenols, tocopherols, chlorophylls, carotenoid, 
menadione, plastochromanol-8 and oryzanols) seem to play an additional role in glycation reactions 
[25]. Finally, grape by-products revealed that they may function as potential antioxidants and also as 
therapeutic agents against bacterial colonization, obesity, thrombotic events and carcinogenic 
processes, mainly due to the polyphenols (PCs) and dietary fiber (DF) content [26]. Nevertheless, 
before these by-products become available in clinic as AGE inhibitors, there is a need for further 
studies regarding their toxicity, such as the presence of either residual pesticides or heavy metals [26]. 
 
Figure 1. Main characteristics of pancreatic function in healthy individuals versus in diabetic 
individuals. In heathy individuals, the pancreas responds to hyperglycaemia with insulin secretion 
aiming to maintain gluco-homeostasis. Diabetes occurs when the pancreas fails to produce insulin, 
DMT1, insulin-dependent, or when insulin produced is insufficient or unable to produce gluco-
homeostasis (DMT1). 
When there is an increase in glycemia, glycolysis, glycogenesis and lipogenesis are increased 
while gluconeogenesis, glycogenolysis and lipogenolysis (mainly due to hormone action) decrease in 
order to restore normal glucose levels by promoting glucose reservation and degradation. When 
glycemia decreases, the opposite is observed [24,26]. Since lipids serve as a substrate for glucose 
production, DM, obesity and other metabolic conditions are straightly correlated, thus explaining 
why metabolic syndrome is inevitably increasing among humans [27–30]. 
The early onset of atherosclerosis and also the multiple mechanisms that contribute to arterial 
diseases in T2DM patients are closely associated with both dyslipidemia and hyperhomocysteinemia 
[31]. There is a correlation between the high burden of abdominal fat and the elevated levels of free 
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fatty acids (FFA) that enrich the liver through portal circulation. This contributes to an 
overproduction of TG-rich lipoprotein particles, including very-low-density lipoprotein (VLDL) 
cholesterol (VLDL-CH) and low-density lipoprotein cholesterol (LDL-CH), a decrease in high-
density lipoprotein (HDL) cholesterol (HDL-CH) and hypertriglyceridemia [7]. Besides 
hyperglycemia, systemic or local insulin levels elevation may contribute to abnormal lipid 
metabolism and a compromised endothelial function, because (i) the concentration and composition 
of potential atherogenic lipoproteins may be altered; (ii) changes in the apolipoprotein ratio observed 
in HDL can possibly interfere with its protective role in vascular disease; and (iii) insulin seems to 
play a direct role in blood vessel walls by increasing the levels of cellular cholesterol as it promotes 
an increase in cellular sterol synthesis, induction of the LDL receptors and inhibition of HDL-
mediated cholesterol removal [7,31]. 
Nearly 80% of the T2DM patients are overweight [1]. In fact, obesity is considered a major public 
health problem and a relevant risk factor for numerous metabolic diseases, such as heart disease, 
cancer, arthritis and T2DM [16,31]. Its prevalence has been increasing worldwide with about 162 
million as of 2015, and it is also of concern the increasing identification of obesity- and leanness-
susceptible loci in humans [1]. Obese individuals have both an increased resistance to insulin and an 
impaired suppression of glucose hepatic production, leading to elevated glucose and insulin levels 
[1]. It was reported that a greater risk for metabolic disorders is associated with people who have 
upper body obesity, i.e., central obesity rather than those with lower body obesity. Peripheral 
resistance to insulin action and an increased production of glucose in obese people with T2DM may 
be due to an increased concentration of free fatty acids (FFAs), and visceral obesity is especially 
important because it is accompanied by increases in fasting and postprandial FFA concentrations, 
which contribute to: (i) stimulated insulin secretion (if acutely) or lipotoxicity (if chronic) by 
pancreatic β-cell; (ii) inhibited glucose uptake and glycogen storage in peripheral tissues by reducing 
muscle glycogen synthetase activity, leading to insulin resistance and glucose underutilization; and 
(iii) increased hepatic glucose production and hyperglycemia, especially in fasting plasma glucose 
levels, increasing the accumulation of FFAs and triglycerides that leads to  reduced hepatic insulin 
sensitivity [1]. Thus, an increase in FFA allied with T2DM genetic predisposition in obese individuals 
may lead to the triad: β-cell failure, peripheral insulin resistance and abnormal hepatic glucose 
production. 
On the other hand, low blood levels of adiponectin, an adipocytokine secreted by adipose tissue, 
have been shown to contribute to insulin resistance in animal models and patients with obesity and 
T2DM [1]. Moreover, adiponectin mRNA expression may be partially regulated by a nuclear receptor, 
the peroxisome proliferator activated receptor γ (PPARγ), since it regulates the expression of genes 
controlling FFA levels and glucose metabolism. In skeletal muscle, adiponectin increases fatty acids 
use as a fuel source, decreasing the tissue triglyceride content. As in MS, adiponectin levels are so 
low that compromise the function of this protein hormone, and adiponectin has been considered an 
alternatively pharmacological target to the treatment of insulin resistance. Furthermore, natural 
alternative agents, in the form of beverages or tea, have already demonstrated to succeed in obesity 
treatment, attenuating adverse effects of chemically formulated anti-obesity agents [1]. 
Moreover, gender differences had been observed in T2DM patients: T2DM is more frequently 
diagnosed in men of younger age and body mass index whereas obesity, the main risk factor, is more 
commonly seen in women [32]. Sex hormones have been demonstrated to play an important role in 
energy metabolism, body constitution, blood vessel function, and inflammatory processes. 
Nutrition therapy is an important part of the treatment of T2DM, showing beneficial outcomes, 
together with patient education for self-management and physical activity practice, on body weight, 
metabolic control, and wellbeing. Thus, international guidelines have long recommended an 
individualized nutrition therapy for all diabetic individuals. The majority of patients may 
simultaneously require pharmacological therapy, which acts on at least one of several possible 
known targets (Table 1) [33]. 
Table 1. Main targets of the hypoglycemic drugs currently approved for the treatment of diabetes 
mellitus (Adapted from [33]). 
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Drug Targets Hyperglycemic Effect Observed with: 
Insulin secretion 
↗ Incretins 
↗ Meglitinides 
↗Sulfonylureas 
Glucagon secretion 
↓ incretins 
↓ amylin 
Gastrointestinal tract 
Incretins 
Alpha-glucosidase inhibitors 
Amylin 
Sequestrant of bile salt 
Hepatic glucose output 
↓ Metformin 
↓ Thiazolidinediones 
Lipotoxicity Thiazolidinediones 
Control of appetite 
Incretins 
Amylin 
Neurotransmitter Dysfunction Bromocriptine 
Glucose reabsorption ↓ Gliflozins inhibitors 
Glucose uptake and use 
↗ Metformin 
↗ Thiazolidinediones 
3. Oral and Injectable Hypoglycemic Drugs Overview 
3.1. Registered Approaches 
Marketed oral and injectable non-insulin antidiabetic agents (Figure 2) have been demonstrated 
to be effective but they possess several adverse effects that contribute to consider the diabetes 
treatment approach with no adverse effects a challenge. 
 
Figure 2. Oral and injectable non-insulin glucose-lowering drugs approved by the American Diabetes 
Association. 
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3.1.1. Sulphonylureas 
Sulphonylureas have been commercially available since the 1950s and may be considered in 
individuals that cannot maintain a controlled diet or drug treatment other than this [23]. 
Sulphonylureas have a rapid intestinal absorption, thus increasing the insulin produced by the 
pancreas. They include glipizide, glimepiride and glyburide. When compared to first-generation, 
second- and third-generation sulfonylureas are able to penetrate cell membranes more promptly 
because of their higher lipid solubility and greater selective binding capacity [23]. 
As insulin secretagogues, sulphonylureas are able to reduce glycemia levels by direct 
stimulation of the pancreatic β-cell glucose-independent insulin secretion: they bind to one of the 
subunits of the K-ATP channel on the plasmatic membrane, sulfonylurea receptor type 1 (SUR1), and 
to the protein Epac2, enhancing the closure of the K-ATP channel, leading to cell depolarization and 
consequent insulin secretion [33]. 
Along with hypoglycemia, adverse cardiovascular effects have been found in some 
observational studies; findings from recent high-quality systematic reviews showed no increase in 
global mortality risk related to sulphonylurea use in comparison to other pharmacologic therapeutic 
options [23,34]. 
3.1.2. Biguanides 
Biguanides is the other class of oral anti-diabetic agents which is adequate for all types of DM. 
They reduce glucose absorption from the intestine, prevent liver glucose production and improve 
insulin’s sensitivity. Biguanides can also be used to treat mild diabetes in pregnant women [7]. 
Highlighting metformin, which is a guanidine synthetic analog and the orally administered drug 
most frequently prescribed for T2DM treatment in any age, it is known that this biguanide acts by 
activation of the hepatic adenosine monophosphate-activated protein kinase, thus promoting an 
increased glucose uptake by the hepatocytes and also a complex alteration in mitochondrial enzyme 
apparatus leading to gluconeogenesis inhibition [35]. In addition, it reduces free fatty acid plasma 
concentration, thus contributing to the gluconeogenesis reduction [36]. It was demonstrated that 
plasma free fatty acids largely participate in regulating glucose production in the liver. Moreover, by 
the reduction of glucose production rates in liver, metformin also reduces fasting plasma glucose 
concentrations [36]. Finally, metformin is also able to increase intestinal glucose utilization and to 
stimulate GLP-1 secretion [33]. Side effects of metformin are restricted to the gastrointestinal tract 
such as abdominal discomfort and diarrhea [31]. Lactic acidosis is rare, occurring mostly in patients 
with impaired renal function [31]. 
3.1.3. Thiazolidinediones 
Thiazolidinediones (TZDs) regulate gene expression, in order to enhance insulin activity in all 
body tissues, just by interacting with a nuclear receptor family, the peroxisome proliferator-activated 
receptors (PPARs) [37]. 
In this sense, cigliatazone, pioglitazone, troglitazone and englitazone have proved to be useful 
insulin sensitizing agents [38]. Activation of PPAR-γ by the thiazolidinediones contributes to 
maintain glucose homeostasis, improve insulin action and also prevent impaired glucose tolerance 
in patients [39]. Studies of the TZD action in adipose tissue have shown that they alter leptin, 
inflammatory molecules, and circulating proteins (such as tumor necrosis factor alpha, TNF-α) 
expression, thus eventually contributing to the characteristic peripheral insulin resistance [39]. 
Studies in animals and humans suggest that TZDs may help preserve β-cell function and thereby 
delay progression of T2DM [40]. 
Pioglitazone, a marketed TZD, is orally administered for the treatment of T2DM and contributes 
to increase the transcription of several regulating proteins implicated in glucose and lipid 
metabolisms by amplifying the post-receptor insulin action in body tissues, thus leading to an 
improvement in glycemic control with no associated insulin endogenous secretion enhancement. 
Pioglitazone co-treatment was reported to significantly decrease both HbA1c and fasting blood 
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glucose levels in patients with a poorly controlled disease [41]. Moreover, pioglitazone has also been 
implicated in serum lipid profile improvement in randomized placebo-controlled clinical studies 
[39]. The drug is usually well tolerated by any age adult and was proven to reduce cardiovascular 
events [39,42]. 
Common side effects associated with TZDs include edema, weight gain, macular edema and 
heart failure. Increased bone fracture risk is another TZD-related side effect. Hepatic dysfunction (2% 
incidence), sometimes leading to liver failure, is a serious problem with troglitazone but not with 
rosiglitazone. However, rosiglitazone has been associated with an increase in myocardial infarction 
incidence [42]. Moreover, CYP3A4 (cytochrome P450 isoform) is induced by both troglitazone and 
pioglitazone, thus playing an important role in their metabolism. Safety and efficacy could be affected 
when these agents are co-administered with other drugs metabolized via this enzyme [42]. 
3.1.4. α-Glucosidase Inhibitors 
This class of drugs reduces intestinal glucose absorption [43] by delaying carbohydrate 
digestion. Highlighting acarbose, miglitol and voglibose competitively inhibit α-glucosidases, an 
important family of intestinal enzymes that participate in carbohydrates digestion. It is known that 
they decrease postprandial elevated blood glucose levels and elevated insulin, thus improving the 
insulin cell sensitivity and minimizing β-cells stress [43]. Additionally, these compounds have the 
advantage of not inducing hypoglycemia and having a satisfactory safety profile, even if associated 
with some gastrointestinal adverse effects that may result in difficult long-term compliance to this 
therapeutic option [43–45]. 
3.1.5. Sodium-Glucose Co-Transporter Type 2 (SGLT2) Inhibitors 
Sodium–glucose co-transporter type 2 (SGLT2) inhibitors consist of recently discovered anti-
hyperglycemic agents which have a particular insulin-independent mode of action: since SGLT2s are 
mainly expressed in proximal renal tubules and is responsible for almost 90% of filtered glucose re-
uptake, they preferably target the kidney, blocking glucose reabsorption and thus promote increased 
urinary glucose excretion (UGE), especially in hyperglycemic situations [9,46]. This particular 
mechanism of action seems to be promising for T2DM patients because patients improve glycemic 
control, with a low risk for hypoglycemia, and they have demonstrated benefits on weight loss, 
mainly due to the increased glucosuria in association with arterial blood pressure reduction, both 
providing an osmotic effect [9,46]. 
The favorable pharmacokinetic properties of SGLT2 inhibitors, namely, their excellent oral 
bioavailability, rather long elimination half-life that allows a single daily administration, reduced 
accumulation index, no active metabolites, limited renal excretion and low risk of DDIs, contribute 
to an increasingly interest in these compounds as oral anti-diabetic drugs [9]. 
Recent studies have proven that it is possible to normalize glycemic levels by inhibiting SGLT2, 
thereby preventing glucose reabsorption through these co-transporters and then re-entering the 
circulation. This insulin-independent mechanism decreases blood pressure, individual weight and 
plasma glucose levels without causing hypoglycemia [9,46]. 
Several SGLT2 inhibitors are marketed around the world, namely, dapagliflozin, canagliflozin 
and empagliflozin, in Europe and the United States and ipragliflozin, luseogliflozin and tofogliflozin, 
in Japan. Also relevant are ertugliflozin and remogliflozin, among others, which are already in the 
late phase of development [3,9]. They can be used either as monotherapy in diet-treated patients or 
combined with any other anti-glycemic agent [9]. 
SGLT2 inhibitors have documented a good safety profile, with low risk for hypoglycemia and 
high risk for both benign urinary tract and fungal genital infections [9]. Playing a vital role in 
carbohydrate metabolism, the kidney is responsible for the recovering the glucose presented in the 
glomerular filtrate under SGLT2 control, and SGLT2 inhibitors have demonstrated to be as effective 
as other current antihyperglycemic drugs (namely, metformin, sulphonylureas and sitagliptin). 
SGLT2 inhibitors may be regarded as a major approach of insulin-independent reducing 
hyperglycemia agents for T2DM treatment [3,9]. 
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3.1.6. Dual SGLT1/SGLT2 Agonists 
A great effort has been made to discover agonists that act on both SGLT1 and SGLT2 receptors. 
The first developed dual combined SGLT1/SGLT2 inhibitor, sotagliflozin (LX4211), acts by blocking 
small intestinal SGLT1 and renal SGLT2 and SGLT1 (SGLT2, proximal convoluted tubule; SLGT1 
proximal strait tubule), thus producing a diminished early phase on the absorption of glucose, 
reducing postprandial glycemia and insulin secretion, and increasing GLP-1 and peptide YY (PYY) 
circulating levels [47–49]. Initially, studies focused on T1DM and sotagliflozin revealed HbA1c and 
glucose variability reduction [47]. The program was recently extended to T2DM trials, although long-
term studies will be fundamental to evaluate the risk-benefit ratio for this agent to be used as an 
alternative to the traditional SGLT2 inhibitors [47]. When compared to single SGLT2 inhibitors, 
sotagliflozin has similar potency for SGLT2 inhibition but 0.10-fold higher with respect to SGLT1 
inhibition [50]. All the results indicate a great potential for SGLT1 inhibition with minimal glucosuria 
and an adequate therapeutic window, together with blood pressure and body weight favorable 
modifications [50]. 
3.1.7. Glucagon-Like Peptide-1 amide (GLP-1) Receptor Agonists 
GLP-1 receptor agonists and their analogues (incretin mimetics) constitute a new antidiabetic 
class of drugs that are responsible for the enhancement of glucose-dependent insulin secretion, 
suppression of glucagon release and pancreatic β-cells protection [46,51]. Any evidence of differences 
between natural GLP-1 and its analogues might probably be a consequence of the introduced 
modification for prolonged pharmacological action, which should be further discussed in order to 
improve the use and design of such analogues [51]. 
Injectable GLP-1 receptor agonists, such as exenatide, liraglutide, lixisenatide, albiglutide and 
dulaglutide, enhance insulin release induced by nutrients, inhibit glucagon secretion, delay gastric 
emptying and promote satiety, which lead to weight control [51]. Furthermore, an increase in β-cell 
mass in animals has also been reported [51]. 
The optimal therapeutic effect of GLP-1 agonists was found to be only achievable under 
provided regimens of sustained plasma levels of active peptide, which include a continuous 
subcutaneous infusion (CSCI) of GLP-1 and GLP-1 analogue injections at a time or two per day or 
even weekly with extended plasma stability [51]. 
Recombinant glucagon-like peptide-1 (rGLP-1) has major similarity to the native and synthetic 
GLP-1 sequence. In a recent study covering regimens of continuous subcutaneous infusion (CSCI) of 
rGLP-1, over 3 months and combined with metformin and sulphonylurea, this GLP-1 analogue was 
able to decrease glycated hemoglobin (HbA1c) and fasting plasma glucose, and significantly reduce 
body weight (sometimes not so well achieved) in a dose-dependent manner [51]. GLP-1 receptor 
agonists may therefore be considered a future approach in the treatment of T2DM [46,51]. 
3.1.8. Dipeptidyl-peptidase-4 (DPP4) Inhibitors 
Dipeptidyl-peptidase-4 (DPP4) is the enzyme responsible for the rapid inactivation of the 
incretins GLP-1 and GIP [52]. Dipeptidyl-peptidase-4 (DPP4) inhibitors, namely, linagliptin, 
vildagliptin, sitagliptin, saxagliptin, and alogliptin, are once or twice-daily oral drugs which enhance 
endogenous effects of incretin by means of DPP4 inhibition, thus retarding incretin degradation and 
prolonging their circulating half-lives [46]. 
3.1.9. Bile Acid Sequestrants 
Bile acid sequestrants (BAS) are considered a good approach to T2DM treatment since 
dyslipidemia is known to exacerbate T2DM-related cardiovascular complications and these 
compounds have both glucose and lipid lowering action in clinical trials [53]. BAS produce a 
nonabsorbable complex that avoids bile acid reabsorption, thus increasing its intestinal excretion [54]. 
This, in consequence, promotes more bile acids to be synthetized and transforms low-density 
lipoprotein (LDL) cholesterol into bile acids, promoting a reduction in plasma LDL levels [54]. A 
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systematic review regarding meta-analyses of randomized controlled trials showed that diabetic 
patients treated with BAS reported a glycemic control improvement (HbA1c reduced 0.55% in end of 
treatment trials and 0.40% in mean change trials) and reduction on LDL cholesterol levels (not so 
significant as with statin treatment), with no apparent influence on weight [54]. Some gastrointestinal 
adverse events (constipation was the most common) and triglyceridemia elevation were observed 
but not significant to display clinical evidence [54]. Colesevelam (second-generation) was the only 
BAS approved by the US Food and Drug Administration (FDA) for hyperglycemia treatment in 
T2DM patients, in 2008 [53,54]. 
3.1.10. Dopamine Type 2 Receptor Agonists 
Bromocriptine (BC), a dopamine type 2 receptor (D2R) agonist, was the first approved and 
patented dopaminergic drug for T2DM treatment, by the FDA in 2009 (quick-release formulation- 
bromocriptine-QR) [55–57]. Several tests have been performed since then. For instance, in an alloxan-
induced diabetic rat model, BC anti-hyperglycaemic effect was tested, either with or without 
concomitant glipizide: when administered alone, bromocriptine was found to lower glycemia values 
and this result was several times potentiated with glipizide co-administration, thus indicating that 
bromocriptine must be considered for adjuvant anti-diabetic therapy [55]. Another study was 
performed administrating BC-QR in D2R knockout mutant mice, with glucose intolerance and 
impaired insulin secretion, revealed fasting glucose, lipolyisis and lipogenesis reduction and less severe 
adverse effects and cardiovascular disease manifestations [55,57]. In obese men, weight loss, body fat 
loss and glucose tolerance improvement were reported [57]. Thus, bromocriptine decreases insulin 
resistance and glucose synthesis in the liver by potentiating dopaminergic neurotransmission which in 
turn resets the hypothalamus and enhances insulin sensitivity in body tissues [55]. Further clinical trials 
must be performed to confirm the above-mentioned findings, and although a protective effect of BC on 
pancreatic beta-cells endogenous insulin secretory capacity has been reported, the FDA does not 
recommend its use in T1DM [57]. Finally, this evidence indicates that insulin secretion is not only 
glucose-regulated but is also controlled by parasympathetic or sympathetic input, especially from the 
dopaminergic system [57]. 
3.1.11. Amylin Mimetics 
Amylin is a ~4 kDa peptide hormone co-secreted by pancreatic beta-cells with insulin and is 
responsible for maintaining glucose metabolism homeostasis [58]. It acts by activation of amylin 
receptors, some of them shared with calcitonin gene-related peptide (CGRP). This peptide modulates 
ingestion (induces satiety) and reduce both insulin secretion and sensitivity although with a short 
half-life of 13 min [58–60]. Amylin mimetics have been developed regarding weight loss in 
overweight diabetic patients, usually participating in a combined therapy approach where leptin 
seemed to be a good option: amylin may enhance leptin sensitivity and prevent leptin resistance [59]. 
At the moment, pramlintide is the only one available on the market for clinical use in both T1DM and 
T2DM. Next-generation amylin mimetics with improved pharmacokinetics have been developed as 
anti-obesity strategies: (i) davalintide, a much more potent and effective agent, with greater affinity 
to human CGRP receptor and a prolonged action; (ii) PEGylated or glycosylated amylin, whose chain 
was modified by either polyethylene glycol (PEG) coupling or glycosylation, thus having a greater 
half-life (~10 h 15); and finally (iii) dual amylin and calcitonin receptor agonists (DACRA), KBP 042, 
KBP 088 and KBP 089, which bind to both amylin and calcitonin receptors and produce a greater 
eating inhibition [59]. 
3.2. Novel Approaches 
Synthetic compounds seem to be promising future treatment approaches in T2DM and MS 
treatment. 
3.2.1. Mangiferin-Berberine Salt 
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Mangiferin is a xanthone glycoside extracted from Mangifera indica and Anemarrhena 
asphodeloides. It has hypolipidemic, hypoglycemic, insulin-sensitizing, anti-obesity, antioxidant and 
anti-inflammatory properties in animal models and also in clinical studies, probably due to the 
activation of AMP-activated protein kinase (AMPK) [41]. As a result of this activation, the energy 
balance can be controlled and hence, lipid and glucose metabolisms [41]. Berberine is an isoquinoline 
alkaloid isolated from Coptis chinensis that seems to be a promising agent in modulation of both 
carbohydrate and fat metabolisms, by means of LDL receptor upregulation, modulation of the 
intestinal microbiota and the activation of AMPK [41]. 
Mangiferin-berberine salt is a synthetic compound obtained from mangiferin (M) and berberine 
(B) chemical bonding at an equal molecular ratio; it presents an acidic M group conjugated with an 
alkaline B group by ionic bond forming a stable single molecule [41]. As M and B roles in the 
improvement of metabolic disorders are undeniable, it was thought that MB salt could also have 
beneficial modulatory activities in carbohydrate and fat metabolisms [40]. In fact, recent pilot studies 
demonstrated that the mangiferin-berberine salt (1) stimulates the AMPK signaling pathway in L6 
skeletal muscle cells, (2) lowers both glucose and lipids levels in blood and (3) improves insulin 
sensitivity and liver function in KK-Ay diabetic mice models [41]. Furthermore, efficacy studies 
performed on the HepG2 cell line corroborated that MB salt truly has a potent stimulating activity in 
AMPK and in modulating carbohydrate and fat metabolisms; these properties have shown to be 
better than the ones found for M or B alone [41]. 
MB salt is therefore a promising antidiabetic agent as it is able to (1) act as a potent AMPK 
activator, suppressing gluconeogenesis, (2) prevent hepatic steatosis and reduce the triglyceride (TG) 
content in hepatocytes, (3) suppress the upregulation of lipogenic and diabetic genes, attenuating 
lipogenesis, (4) stimulate basal and insulin-stimulated glucose consumption, (5) stimulate glucose 
metabolism having no insulin, (6) inhibit glucose production and (7) downregulate PEPCK/G6Pase, 
without cellular toxicity and in a dose-dependent manner [41]. 
3.2.2. β-tigogenin Cellobioside (Tiqueside) 
Saponins, either natural or synthetic, can function to reduce cholesterol absorption and 
plasmatic levels, having an increasing interest in hypercholesterolemia management [61]. Aiming at 
determining the properties of saponins in lipid metabolism, a study was carried out using the 
synthetic soponin β-tigogenin cellobioside, also named tiqueside or CP-88818, on male golden Syrian 
hamsters [61]. It was found that tiqueside could reduce cholesterol absorption, depending on the 
administered dose, either in the presence or absence of exogenous cholesterol [36]. In addition, the 
administration of tiqueside to chow-fed hamsters contributed to decrease intestinal cholesterol 
absorption without any alterations in bile absorption or 7α-hydroxylase cholesterol activity, thus 
suggesting no interference in enterohepatic bile acid recirculation [61]. Furthermore, cholesterol 
levels in liver were reduced in a dose-dependent manner and were correlated with an inhibition of 
cholesterol absorption; an induced compensatory increase in the activities of both intestinal HMG-
CoA reductase and hepatic LDL receptor levels were also registered [61]. Among other animal 
species, tiqueside also produced plasma cholesterol lowering, either with diets containing cholesterol 
(hamster, rat, mouse and dog) or diets without it (hamster, rat, rabbit, mouse, cynomolgus monkey, 
rhesus monkey and SEA quail), which suggests a broad action [61]. Except for dogs, plasma 
cholesterol reduction was mainly due to blood non-HDL cholesterol lowering levels with a small or 
even no alteration in circulating HDL cholesterol levels. 
Tiqueside inhibits cholesterol absorption, producing large effects on cholesterol metabolism, 
leading firstly to a reduction of circulating non-HDL cholesterol, with no alteration in bile acid 
metabolism [61]. Synthetic saponins, such as tiqueside, may thus be regarded as a potential treatment 
of hypercholesterolemia and in this way, also contributing to metabolic syndrome and T2DM 
management [61]. 
3.2.3. Incretin-Based Therapies 
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Insulin secretion is admittedly much greater after glucose oral intake than after endovenous 
administration, which may indicate that insulin is secreted by means of stimulating factors related to 
sugar ingestion, incretins, that act as intestinal tract messengers [15]. Incretins are a group of 
metabolic hormones that share a postprandial hypoglycemic effect and an enhancement of insulin 
secretion by pancreatic β-cells by means of a glucose-dependent mechanism, and that also inhibit 
glucagon secretion by α-pancreatic cells [62]. The two main molecules belonging to this class are the 
intestinal peptides glucagon-like peptide-1 amine (GLP-1) and glucose-dependent insulinotropic 
polypeptide (GIP), although T2DM patients seem to have no major GIP secretory defect [15,63]. Both 
of them are inactivated by the enzyme dipeptidyl peptidase-4 (DDP4) very rapidly [63]. Incretin-
based therapies have huge potential in T2DM treatment [46,63]. Among the available therapies, three 
of them dominate, namely, glucagon-like peptide-1 amide receptor agonists, dipeptidyl-peptidase-4 
inhibitors and Takeda-G-protein-receptor-5 (TGR5) agonists [46]. 
3.2.4. TGR 5 Agonists 
TGR5 bile acid receptors, also named G protein-coupled bile acid receptor 1 (GPBAR 1), G-
protein-coupled receptor 19 (GPCR19) or membrane-type receptor for bile acids (M-BAR), are 
membrane receptors specific to bile acids, present in L cells, that stimulate GLP-1 secretion [46]. 
Preliminary studies are being performed in order to evaluate if TGR5 agonists, which are barely 
absorbed, may act further along the intestinal tract, mainly in the ileum, to enhance GLP1 secretion 
by activating these TGR5 receptors in L cells, as it has been demonstrated in other performed studies 
with colesevelam, a bile acid sequestrant indicated as a glucose-lowering drug in some countries [46]. 
TGR5 agonists may be then considered promising antidiabetic agents and a future approach for 
T2DM drug therapy [46]. 
3.2.5. β-Cell Acting Compounds 
Since there is a great need for lasting efficacy interventions able to prevent, attenuate and/or 
reverse pancreatic β-cell dysfunction and β-cell mass reduction in T2DM patients, compounds found 
to act in pancreatic β-cells may be considered an excellent approach for drug therapy [46]. 
Four classes, namely, small molecule insulin releasers, glucokinase activators, fatty acid receptor 
agonists and imeglimin, are currently under investigation and will be discussed in the next sections 
[46]. 
3.2.6. Small-Molecule Insulin Releasers 
Small molecule insulin releasers, namely, succinate esters, imidazolines, selective phosphor-
diesterase inhibitors, antagonists of α2 adrenergic receptors, and agents that close potassium 
channels or open membrane calcium channels, have shown to improve β-cell function in vitro, by a 
mechanism similar to that of current antidiabetic agents, such as sulfonylureas and meglitinides. 
However, it is important to note that in vivo experiments have demonstrated that these promising 
compounds are non-specific in targeting pancreatic β-cells [46]. 
Further investigation is thus required for a better understanding of their biological targets and 
possible biological effects. 
3.2.7. Glucokinase Activators 
The action of glucokinase, a glucose phosphorylating enzyme, can be enhanced by glucokinase 
activators [46]. Glucose phosphorylation prevents glucose leak from the cell and prepares it for 
further metabolism. Glucokinase present in pancreatic islet β cells functions as a glucose sensor. 
Additionally, it plays also an important role in both hepatic glycogenesis, where small molecules of 
glucose are joined together and converted into a glycogen molecule, and liver gluconeogenesis 
regulation [64]. Therefore, glucokinase activators lead to an increase in insulin secretion and also in 
hepatic glucose metabolism, thus, decreasing blood glucose levels [46]. When stimulating insulin 
secretion at low glucose levels, they seem to promote hypoglycemia [46]. 
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Since glucokinase has a different regulation mechanism in liver cells compared to that in the 
pancreas, future investigations should focus on liver-selective glucokinase activators and compounds 
that also share an ability to enhance futile cycling of hepatic triglycerides, during a prolonged action 
of glucokinase in the liver [46]. 
Moreover, recent investigations using mice genetically modified for glucokinase and also those 
in mutated humans have highlighted how glucokinase is relevant in maintaining carbohydrate 
homeostasis, thus considering that pharmacotherapies that enhance glucokinase biological activities 
may be a promising approach for T2DM treatment [65]. 
3.2.8. Fatty Acid Receptor Agonists 
Free fatty acids can function as a ligand for several G-protein coupled receptors (GPR) [46]. 
Once activated, the receptors are expressed in pancreatic β-cells, e.g., GPR40 (also referred as 
FFAR1) and GPR119, contribute to enhance insulin secretion; although, as they are also expressed in 
α-cells, they contribute to an undesirable glucagon enhanced secretion [46]. 
These receptors are also expressed by other cells, such as other enteroendocrine pancreatic cells, 
K cells, L cells and I cells [46]. 
With respect to the mechanisms of action, while GPR40 agonists increase calcium concentration 
in the cytosol, stimulating insulin secretion, GPR119 agonists activate adenylate cyclase cascade 
leading to augmented levels of adenosine monophosphate and the potentiation of nutrient-induced 
insulin secretion [46]. 
Furthermore, the receptor GPR120, which is mainly expressed by adipocytes, promotes 
adipogenesis [46]. Synthetic agonists for the referred receptors lead to an increased secretion of several 
hormones, such as GIP, GLP-1, peptide YY (PYY) and cholecystokinin (CCK), thus potentiating the 
incretin and satiety effects of these hormones, and also increase insulin sensitivity [46]. 
3.2.9. Imeglimin 
Imeglimin, a triazine derivative, stimulates glucose-induced insulin secretion and improves 
glycemic control in T2DM patients. It is believed that this compound may change cellular energetics, 
partially due to a closure of mitochondrial permeability transition pores, and also improve insulin 
sensitivity at the periphery and reduce hepatic gluconeogenesis [46]. 
3.2.10. Adipokine-Based Treatments 
There are several adipocyte hormones that play an important role in energy metabolism. Leptin 
stimulates insulin and inhibits glucagon actions, besides promoting weight loss by means of central 
satiety and thermogenic effects [66,67]. However, the effects of this hormone and its analogues could 
only be achieved in T2DM patients who suffer from severe leptin deficiency [46]. 
Adiponectin, usually at low concentrations among T2DM patients (especially in overweight 
ones), is responsible for insulin sensitivity improvement, endothelial function enhancement and an 
anti-inflammatory effect. Therefore, in recent studies, the orally active adiponectin receptor agonists, 
ADIPOR 1 and ADIPOR 2, have been demonstrated to have glycemic control improvement and the 
extension of the lifespan of insulin resistant diabetic animals, being regarded as new promising 
agents for clinical trials [46]. 
Retinol-binding protein 4 (RBP4) is a plasma retinoid transporter detected in the early phase of 
insulin resistance conditions, such as in T2DM and MS; its inhibition allowed an increase in insulin 
sensitivity in animal trials [46]. 
Fibroblast growth factor 21 (FGF21) may be considered as a distinct member of the FGF family 
due to its properties in the endocrine system. Although with a predominant hepatic expression, it is 
also found in the pancreas and adipose tissue. Pharmacological a peptide secreted by adipocytes, 
hepatocytes and myocytes, contributes to fatty acid β-oxidation and gluconeogenesis in the liver 
during starvation. Since FGF21 is elevated in the plasma of T2DM patients and obese individuals, 
mainly due to FGF21 resistance, the administration of FGF21 analogues seems to be a favorable 
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approach as they probably will lead to an improvement of the lipid profile, reduction of insulin 
resistance and glucose-lowering, in part due to the increased adiponectin production [46]. 
3.2.11. Selective Peroxisome Proliferator-Activated Receptor (PPAR) Modulators 
PPAR is a family of nuclear receptor proteins that function in transcription in cells, playing an 
essential role in regulating cellular differentiation, development and carbohydrate, lipid and protein 
metabolism [46] There are three types currently well identified: (i) PPARα, responsible for the 
improvement of the lipid profile, inflammation process attenuation and management of 
microvascular complications, although it is known that it may raise creatinine levels and the risk for 
myopathological abnormalities, (ii) PPARβ/δ, which contributes to weight gain by increasing 
thermogenic energy expenditure, and (iii) PPARγ, which leads to insulin sensitivity improvement, 
glycemic control and participates as a vascular health marker, also reducing inflammation, but it also 
contributes to increase fluid retention and heart failure risk, bone mineral density reduction and 
enhanced adipogenesis [46]. 
Although they have shown promising therapeutic effects, PPAR selective agonists—dual 
PPARα/γ agonists (or glitazars) and triple PPARα/γ/δ agonists (or panPPARs)—were not applied in 
clinical use due to the reported side effects, which need further investigation to be minimized [46]. 
For this reason, selective PPAR modulators (SPPARMs) have been designed in an attempt to 
overcome those undesirable effects. An example of success in recent clinical trials is INT131, a non-
thiazolidinedione that has demonstrated glucose-lowering efficacy with less edema and less weight 
gain when compared with pioglitazone [46]. 
3.2.12. β-hydroxysteroid Dehydrogenase 1 (11βHSD1) Inhibitors 
11β-hydroxysteroid dehydrogenase 1 (11βHSD1), also known as cortisone reductase, is an 
NADPH-dependent enzyme responsible for reducing cortisone to the active hormone cortisol, which 
activates glucocorticoid receptors, being expressed in key metabolic tissues, namely, the liver, 
adipose tissue and central nervous system [46]. 11βHSD1 inhibitors thus lead to a diminished active 
cortisol production [46]. For instance, a recent 12-week randomized phase 2 double blind placebo-
controlled study using INCB13739 in metformin-treated T2DM patients showed an insulin sensitivity 
improvement, HbA1c reduction, lipid profile improvement and body weight reduction [46]. 
Apart from the theoretically promising therapeutic effects in lowering cortisol levels, 11βHSD1 
inhibitors were of low efficacy since a circulating cortisol reduction may occur, thus promoting a 
compensatory adrenocorticotropic hormone increased secretion [46]. 
3.2.13. Antiobesity Drugs 
Since obesity is the major risk factor for T2DM development, there is an evidence that drugs 
currently prescribed for weight loss can also contribute to glycemia control [46]. 
Orlistat, an intestinal lipase inhibitor, and other new satiety-inducing drugs, such as liraglutide 
(high-dose GLP1 receptor agonist), lorcaserin (5-HT2c serotonin receptor agonist) and combinations 
of phentermine-topiramate or bupropion-naltrexone have demonstrated a great potential in T2DM 
treatment [68]. There are further weight-lowering drugs, mainly intestinal satiety hormones, under 
investigation and early development [46]. 
3.2.14. 55.P0110 
For a long time, traditional herbal remedies served as a source of chemical leading structures for 
the design of superior synthetic analogues, compounds that can be traced back to a scaffold of natural 
origin and thus serving as an initial lead for development. This has also been true for diabetes mellitus 
treatment [69]. 
For instance, lupins used in Mediterranean traditional ethnic medicine, have been employed to 
treat diabetes mellitus regarding their antidiabetic activity, due to their abundant quinozolidine 
alkaloid content [69]. These compounds have proven to produce glucose-lowering effects and have 
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a direct insulinotropic action on pancreatic islets when feeding diabetic animals with extracts from 
Lupinus termis or Medicago sativa; lupin alkaloids-rich plants demonstrated an improvement in 
hyperglycemia, hypercholesterinemia and DNA damage [69]. 
55P0110 is one of these synthetic compounds that has been tested for potential antidiabetic 
activity [70]. Despite no evidence of a direct molecular target, it is believed that this compound 
enhances glucose-stimulated insulin release [69]. Since a low potential has been reported for 
hypoglycemia and 55P0110 has proven to be as effective as current established oral antidiabetic 
drugs, next studies are expected to focus on its mechanism of action, i.e., whether the action of this 
new compound involves effects on membrane or nuclear receptors of pancreatic β-cells, such as 
GLPR1, GIPR and GPR40, and/or on their endogenous agonists, thus potentiating glucose-induced 
insulin secretion [69]. Oral bioactive derivatives of (-)-multiflorine previously studied allowed the 
discovery of a novel class of fully synthetic substituted quinazolidines, which have demonstrated 
blood glucose lowering properties [69]. Combined together, all the distinct glucose lowering 
potential, low risk for fasting hypoglycemia and attractive pharmacological profile of 55P0110 and 
analogues, further studies are recommended in order to discover structures for potential antidiabetic 
drugs [69]. 
3.2.15. Antiosteoporotic Trace Minerals: Silicon (Si) and Strontium (Sr) 
Previous studies on soluble silicon (Si) to understand its action on bone metabolism and 
inhibitory effect on PPARγ have been reported. PPARγ participates either in glucose or bone 
metabolism, increases adipogenesis at the expense of osteogenesis, thus contributing to bone loss 
[71,72]. 
A study on obese diabetic KK-Ay mice was carried out to evaluate the anti-diabetic potential of 
bone-seeking Si and stable strontium (Sr), having coral sand (CS) as the natural material containing 
the referred elements [72]. It was found that after 56 days of been fed diets containing CS, there was 
a great decrease in plasma glucose, insulin, leptin, and adiponectin levels and, on the other hand, a 
significant increase in pancreatic PPARγ and adiponectin mRNA expression levels, thus leading to 
an improvement of the β-cells’ glucose sensitivity and a decrease in insulin expression [72]. 
Furthermore, it has been demonstrated that there was an improvement in renal PPARγ, PPARα and 
adiponectin expression, histologic indices of diabetic glomerular lesion and plasma renal function 
indices [72]. 
Taking these results into account, it can be concluded that anti-osteoporotic trace minerals such 
as Si and Sr, due to their demonstrated lowering effect in glycemia, contribution to improve insulin, 
leptin, and adiponectin tolerance and lowering glomerulopathy risk through modulation of related 
pancreatic and renal gene expression, can be regarded as a promising approach to T2DM treatment 
[72]. 
3.2.16. Hybrid Molecules and Hybrid Natural Products 
There has been an increasing interest in producing hybrid molecules in order to combine all the 
beneficial properties and/or roles of several compounds into a single compound [71]. Recent studies 
tried to assess the behavior of hybrid peptides such as GLP1 linked with glucagon, GIP or any other 
intestinal peptide, in an effort to lower blood glucose levels in T2DM patients [73]. Thus, it is possible 
to combine the effects of a great variety of peptides, such as incretins, glucagon receptor agonists or 
antagonists, oxyntomodulin, PYY, obestatin and ghrelin antagonists, for blood glucose and lipid 
levels, satiety, energy expenditure and adiposity, among others [71]. 
In spite of some physicochemical constraints and the need to address some potential 
immunological issues, since these hybrids can be produced with desired sequences to give rise to 
chimeric molecules that interact with specific epitopes and allow novel therapeutic targets in only a 
single molecule, multipurpose designer molecules offer a promising approach in the therapy of 
several conditions, namely, T2DM [71]. 
For the same reason, hybrid natural products, such as O-alkylated xanthone, carbazoles and 
coumarins, have been recently produced. Their anti-diabetic activity has been investigated in vitro 
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regarding their action as inhibitors of the enzymes glucose-6- phosphatase, glycogen phosphorylase 
and α-glucosidase, which are major checkpoints of the sugar metabolism regulation and seem to be 
raised in DM [71]. Inhibiting glucose-6-phosphatase at the penultimate stage of gluconeogenesis 
decreased the hepatic glucose output, thus lowering glucose plasma concentration. On the other 
hand, inhibiting glycogen phosphorylase that contributes to the glucose release from glycogen 
diminished the energy substrate providing for a number of pathways, namely, glycolysis.  Finally, 
inhibiting α-glucosidase, a membrane bound enzyme found in small intestine epithelium, glucose 
cleavage from disaccharide is reduced, thus leading to deficient production of monosaccharides [71]. 
Compounds found to be significant inhibitors were further selected for in vivo testing to evaluate 
their glucose-lowering effect in both sucrose-loaded normal and STZ-induced diabetic rats [71]. 
Although they have obtained some interesting results, there is a need for further investigation, 
since these hybrid compounds seem to be a future natural approach in T2DM treatment and 
management [71]. 
3.2.17. Bis(α-furancarboxylato)oxovanadium (IV) (BFOV) 
Vanadium compounds are nonspecific phosphotyrosine phosphatase inhibitors that have 
proven insulin-mimetic and/or insulin enhancing activity either in vitro or in vivo, countering 
hyperglycemia observed in T1DM human subjects and also maintaining glucose homeostasis in 
T2DM subjects[74,75]. 
The inorganic vanadium salts, vanadyl sulfate and sodium metavanadate, were excluded from 
clinical trials in later phases because of their evidenced low bioavailability and digestive tract 
irritation [74]. To be considered an orally delivered hypoglycemic agent, vanadium needs to cross 
biological membranes in order to be absorbed and undergo intracellular uptake. By means of a 
metallocomplex (complex state of vanadium), most metal ions can pass through cell membranes by 
passive diffusion, since this transporter has low molecular weight, neutral charge, and proper 
resistance against hydrolysis and lipophilicity-hydrophilicity balance [74]. Taking these findings and 
compared to inorganic vanadium salts, vanadium complexes with organic ligands seem to have large 
biological activity with low toxicity [74]. 
Bis(α-furancarboxylato)oxovanadium(IV) (BFOV) is an organic vanadium complex found to 
lower glycemia, intolerance to glucose along with  hyperinsulinemia and also to promote insulin 
sensitivity, activate glucokinase, increase the glycogen content in the liver and suppress 
phosphoenolpyruvate carboxykinase hepatic and renal gene expression in recent studies using fat-
fed/ streptozotocin-diabetic rats [74]. BFOV may thus promote an increase in hepatic glucose disposal 
and ensure carbohydrate homeostasis [74]. 
Furthermore, BFOV holds an almost perfect combination of pharmacokinetic properties, such as 
good water solubility, moderate hydrolytic stability and great lipophilicity, which allow this 
compound to be regarded as a pharmaceutical agent [74]. 
Since BFOV has demonstrated anti-diabetic and insulin-sensitizing activities in diabetic rats, it 
should be regarded as a new orally active anti-diabetic organic vanadium complex that may be 
considered as a promising new therapeutic agent for T2DM treatment [74]. 
3.2.18. LR Compounds: LR-9 and LR-74 
As mentioned in the Introduction of the present paper., the production of Maillard reaction 
products (AGEs/ALEs) is a current clinical concern as they are implicated in the pathogenesis of 
several diabetes mellitus complications [22]. 
Therefore, a great effort in proposing new AGE/ALE formation inhibitors, either of natural or 
synthetic origin, has been made. Besides all the ones mentioned in Section 1., LR-9 and LR-74 were 
recently studied using a streptozotocin (STZ)-induced diabetic rat model [22]. After 32 weeks of 
treatment, it was found that there was a significant inhibition of the albuminuria, creatininemia, 
hyperlipidemia and lipid peroxidation in the plasma, but no considerable effect on hyperglycemia. It 
was also noticed a reduction in (i) renal glomerular and tubular accumulation of CML-AGE, (ii) AGE-
related fluorescence and tail collagen cross-linking, and (iii) skin collagen CML and CEL levels [22]. 
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All these facts suggest that LR-9 and LR-74 may be able to prevent both nephropathy progression 
and dyslipidemia, having an additional antioxidant effect on lipid peroxidation, providing an 
alternative therapeutic option to treat diabetic macrovascular complications [22]. 
3.2.19. Insulinomimetic Zinc (II) Complexes with Natural Products 
Zn(II) ion, an essential trace element, is found in hundreds of metalloproteins and active sites of 
several metalloenzymes and was first reported as an insulin-mimetic agent in 1980, by Coulston and 
Dandona [76]. Further investigation allowed researchers to regard Zn(II) complexes with Zn(O4), 
Zn(N2O2), Zn(N2S2), Zn(O2S2) and Zn(S4) as potent insulin-mimetic agents and thus establish blood 
glucose level reduction in T2DM patients [76]. Finally, in further performed studies, using KK-Ay 
mice, it was reported that Zn(II) complexes with natural products, such as Zn(On) combined with 
betaine (bet), L-lactic acid (lac) and D-(–)-quinic acid (qui), were able to produce glucose-lowering 
effects [73]. Finally, these findings were well observed for Zn(II) complexes with lactic and quinic 
acids, Zn(lac)2 and Zn(qui)2, respectively [76]. 
These findings thus suggest that Zn(II) complexes with natural products may be regarded as a 
future T2DM treatment approach, although there remains a great need for further investigation. 
3.2.20. 4-(2,2-dimethyl-L-oxopropyl)benzoic Acid 
Administrating the compound 2-(1,1-dimethylethyl)-2-(4-methylphenyl)-1,3-dioxolane showed 
reduced glucose plasma levels and fatty acid β-oxidation (FAO), by actively sequestering the 
intramitochondrial CoA required for fatty acids transport into the mitochondria [8]. However, this 
mechanism of CoA sequestrating seems to be harmful to tissues other than the liver that also depend 
on acyl-CoA intermediates processing, thus producing cellular toxicity [8]. Therefore, a prodrug was 
developed in order to increase drug bioavailability at a sufficient rate to inhibit FAO, but easily 
conjugated and eliminated by hepatocytes, through the bile, in order to avoid harmful concentrations 
in the bloodstream [46]. This was achieved by protecting the function of the 4-(2,2-dimethyl-L-
oxopropyl)benzoic acid in a way that only after the cleavage by hepatic nonspecific esterases or P450 
enzymes the prodrug becomes the active compound, thus performing its activity [8]. 
Several polyol esters and ethers of ketone were employed in order to better modulate the 
targeting and release of the active pharmacophore [8]. In future research regarding human subjects, 
it is important to note that ester prodrugs may be species-independent and thus their biological 
activity is similar either in animals or in human subjects; in turn, ether prodrugs and other more 
extensively modified compounds may be demonstrate some differences among species, a fact that 
may affect prodrug activation rate and its reported toxicity effects [8]. 
Hence, 4-(2,2-dimethyl-L-oxopropyl) benzoic acid may be regarded as a novel pharmacological 
agent for T2DM and metabolic syndrome treatment, since it can undergo hepatic activation without 
releasing the active pharmacophore into the bloodstream and thus reducing blood glucose levels by 
inhibiting FAO-dependent gluconeogenesis, without any evidence of toxicity [8].  
3.2.21. Boronated Nucleosides and Nucleotides 
Base-boronated nucleoside and phosphate-boronated nucleotides were found to be good 
hypolipidemic agents in recent animal experiments, since they could lower serum cholesterol and 
triglyceride levels, reduce VLDL and LDL cholesterol levels and elevate HDL cholesterol levels, 
reduce cholesterol, triglyceride and phospholipid levels in tissues, suppress appetite and reduce 
phosphatidylate phosphohydrolase activity, presenting with low toxicity values [77]. They may thus 
be regarded as promising agents in T2DM and metabolic syndrome treatment and management. 
4. Natural Sugar Lowering Compounds 
4.1. Diplacone and Mimulone 
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Diplacone and mimulone are two geranylated flavanones that had anti-inflammatory, 
antiradical, cytoprotective and antibacterial activities in recent in vitro studies and also in an alloxan-
induced diabetic mice model. Diplacone exhibited a cytoprotective effect and a scavenger action on 
superoxide anion and hydrogen peroxide [78]. This has been suggested to result from the structural 
characteristics of the flavonoid skeleton of diplacone, such as the substitution of 5,7-dihydroxy, 4-oxo 
and 3′,4′-dihydroxy (catechol moiety) on rings A, C and B, respectively [78]. The best activity of 
diplacone may be due to the presence of the catechol moiety while the mimulone scavenging ROS 
activity may be due to the single hydroxyl group (para-hydroxyl) present on ring B [78]. 
Furthermore, studies in colitis-induced Wistar rat model diplacone evidenced the best treatment 
profile, with the lowest disease activity index at the last moment of the experimental procedure. Both 
compounds also ameliorated and delayed alterations in stool consistency and rectal bleeding because 
of their potential antioxidant activity, scavenging ROS and interacting with antioxidant enzymes, 
such as superoxide dismutase-2, catalase, cyclooxygenase-2 (COX-2) and matrix metalloproteinase-2 
(MMP-2), responsible for antioxidant defensive mechanisms [43]. Unfortunately, the tested 
compounds could not fully prevent the histological damage and marked shortening of the colon [78]. 
Other flavonoids sharing an anti-inflammatory effect, namely, hesperidin, chrysin, luteolin, icariin 
and EGCG, should also be tested [78]. 
Flavonoids share a great potential as novel anti-inflammatory drugs and they can be thought of 
as new therapeutic approaches against T2DM and/or MS, essentially due to their potential anti-
inflammatory activity [78]. 
4.2. Ethanolic Extract of Semecarpus Anacardium (Linn.) Bark 
Semecarpus anacardium (Linn.), usually known as Beula (Bangla), Bhallataka (Sanskrit) or 
Marking nut tree (English), has been often used in traditional medicine for the treatment of gout, 
rheumatic pain and cancer, due to its immunomodulatory, anti-inflammatory, anti-arthritic and 
anticancer activities mediated by the rich content of phenols, such as carbolic acid derivatives, 
bhilawanols, sterols, glycosides, anacardic acid, anacardoside and flavonoids [7,79]. S. anacardium 
nuts have demonstrated activity in lowering blood glucose and cholesterol levels and also as 
antitumor, antioxidant, cytotoxic, fungistatic, anti-lipid peroxidative and liver protective agents [7]. 
A recent study aimed at determining the effects of ethanolic S. anacardium stem bark extract (i) 
on circulating glucose, hepatic enzymes aspartate aminotransferase (AST/GOT) and alanine 
aminotransferase (ALT/GPT), total cholesterol (TC), triglycerides (TG), LDL- and HDL-cholesterol 
levels, (ii) on hepatic glycogen content, and (iii) as an antioxidant agent in an alloxan-induced diabetic 
rat model [7]. 
The obtained results showed (i) 100% survival rate in rats administrated with the highest 
concentration of the ethanolic extract, (ii) dose-dependent blood glucose lowering level for all tested 
groups, (iii) no meaningful alteration in the ratio of organ weight to body weight, (iv) significant anti-
diabetic effect accompanied by a dose-dependent TC, TG, LDL lowering effect, and (v) assured 
protection of the liver, explained in part by the reduction of GOT and GPT levels and the increase in 
hepatic glycogen [7]. The reported biological activities may be due to rich content of steroids, 
triterpenoids, flavonoids, glycosides, saponins and tannins [7]. 
The ethanolic extract of S. anacardium stem bark presents a higher phenolic and flavonoid 
contents, exhibiting antidiabetic and antioxidant activities, both comparable to metformin 
(commercial antidiabetic drug) and ascorbic acid (antioxidant) [7]. For this reason, the extract of S. 
anacardium can be used as a natural antidiabetic and antioxidant agent, supporting its traditional use 
in the treatment of diabetes mellitus and as a natural source of antioxidants [7]. 
4.3. Catalpol 
Catalpol is an iridoid glycoside that exists in Radix rehmanniae roots [14]. It showed a remarkable 
hypoglycemic effect in a streptozotocin-induced diabetic model, although the underlying mechanism 
of action is not yet fully understood [14]. It was also reported that catalpol is able to: (i) increase the 
expression of glucose transporter subtype 4 (GLUT 4) in skeletal muscle, (ii) ameliorate diabetic 
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encephalopathy (iii) protect neurons against H2O2-induced apoptosis, (iv) participate in some anti-
inflammatory mechanisms, (v) decrease the alterations observed in mitochondrial function, since it 
enhances complex I biologic action and mitochondrial membrane potential, and finally (vi) decrease 
ROS generation [80,81]. 
Since mitochondrial dysfunction participates in the physiopathology of T2DM and the 
improvement of mitochondrial function may contribute to a novel T2DM therapeutic approach, a 
study evaluated the effect of oral catalpol in muscle mitochondria of high-fat diet/streptozotocin 
(HFD/STZ)-induced diabetic mice [14]. Results have proven that catalpol was able to reverse 
mitochondrial dysfunction and increase muscle mitochondrial function and biogenesis, in part by 
means of the mRNA level upregulation of the peroxisome proliferator-activated receptor gamma co-
activator 1 (PGC1α), which is seen especially in body tissues that present a metabolism highly 
oxidative (heart, skeletal muscle, kidney, brown fat, brain and liver), and shares the responsibility to 
regulate mitochondrial biogenesis. HFD/STZ-induced muscle mitochondrial dysfunction was shown 
to be avoided by the interaction between PGC1α and co-activating transcription factors (for example, 
nuclear respiratory factors, thyroid hormones, α and γ glucocorticoid and estrogen-related 
receptors), thus elucidating the PGC1α protective role in mitochondria [14]. Additionally, they have 
been shown to lower circulating total cholesterol and triglyceride levels and fasting blood glucose in 
a dose-dependent manner, without any body weight variation [14]. 
Furthermore, it was found that PGC1α contributed to efficiently raise ATP produced in 
mitochondria, reverse the low potential of the mitochondrial membrane and mtDNA copy number, 
relieve mitochondrial ultrastructure and increase PGC1α mRNA levels, all by a dose-dependent 
upregulation. Thus, when catalpol acts as a stimulus for PGC1α-regulated mitochondrial biogenesis, 
it is capable of lowering the FBG levels, improving mitochondrial function, decreasing oxidative 
stress and reducing insulin resistance, thus functioning as a good novel approach in T2DM treatment 
and MS’ insulin resistance management [14,37]. 
4.4. Apigenin-6-C-2”-O-α-L-rhamnopyranosyl)-β-L-fucopyranoside 
Apigenin-6-C-2”-O-α-L-rhamnopyranosyl)-β-L-fucopyranoside is a compound isolated from 
the leaf extract of Averrhoa carambola L., which belongs to the Oxalidaceae family, believed to be 
implicated in stimulating in vivo 14C-glucose uptake [82]. As a flavonoid-enriched fraction of the 
plant, leaves of A. carambola demonstrated an efficient reduction of glycemia by means of insulin 
secretion stimulation and also by the enhancement of glucose-dependent insulin secretion in diabetic 
rats [82]. Furthermore, this flavonoid-stimulated glucose uptake in rat soleus muscle was driven by 
the well-known insulin signal transduction mechanism. It is important to note that this effect was 
nullified when wortmannin (a phosphatidylinositol 3 kinase (PI3K) inhibitor), RO318220 (a protein 
kinase C inhibitor), mitogen-activated protein kinase (MEK) inhibitor, cycloheximide (a protein 
synthesis inhibitor) or colchicine (a microtubule-depolymerizing agent) was administered [82]. It was 
also shown that apigenin-6-C-2”-O-α-L-rhamnopyranosyl)-β-L-fucopyranoside and insulin share no 
synergistic effect on glucose uptake [30]. This suggests that flavonoids may have a double function, 
either as an insulin-secretagogue or as an insulin-mimetic agent, and thus considered a new approach 
in diabetes treatment [82]. 
4.5. Sophora japonica L. 
Seed, flower and pericarp of Sophora japonica L., from the family Lenguminosea, all contain a 
great variety of antilipogenic flavonoids, including kaempferol, quercetin and genistein, reported to 
have anti-lipogenic effects [83]. Among the several polyphenolic compounds extracted from raw 
products which decrease inflammatory and adipogenic activity in mice, quercetin, found in fruits 
and vegetables, is responsible for inhibiting glucose uptake and increase lipolysis in adipocytes, while 
genistein, abundant in soybeans, can decrease food intake, body weight and fat mass [83,84]. 
Combining together quercetin, genistein and also resveratrol, lipid accumulation significantly 
decreased in adipocyte cell lines [83,85]. 
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Diets with fruits of Sophora japonica L. were found to prevent body weight gain in high-fat diet–
induced obesity, decrease body weight gain, reduce serum and hepatic triglyceride, serum total and 
HDL-CH and decrease large adipocytes and increase small adipocytes in number [83]. These 
antiobesity effects may be due to the anti-adipogenic compound content, namely, flavonoids [83]. 
Since obesity is a major risk factor to the development of insulin resistance and T2DM, 
preventing obesity using mature fruits from S. japonica L. as a phytochemical approach makes it 
possible to control body weight and metabolic diseases with a strict relation to obesity and thus 
managing both MS and T2DM [83]. 
4.6. Water-Soluble Chitosan 
Chitosans belong to a class of natural polymers that are soluble derivatives of chitin, an N-acetyl 
glucosamine polymer and a polysaccharide from the most commonly occurring ones in nature, 
mainly found in clams, shellfish krill, squid, oysters, fungi and insects. As chitin is water-insoluble, 
it is converted to more soluble and lower molecular weight chitosan, a linear copolymer of b-(1,4)-
poly-2-amino-2-deoxy-D-glucose and b-(1,4)-poly-2-acetamido-2-deoxy- -D-glucose, by 
deacetylation and partial hydrolysis reactions [86]. 
From the great variety of applications, such as those in mining, water treatment, paper industry, 
biotechnology, food and cosmetic industries and agriculture, soluble chitosans and their derivatives 
have been increasingly applied in biology and medicine [87–99]. Sustaining this worldwide 
application is the fact that chitosan and derivatives seem to be readily absorbed by enterocytes, have 
low toxicity to eukaryotes, immune system stimulation and hypocholesterolemic and anti-tumor 
activities [38]. Although solubility is the best property of chitosans, it is highly dependent on 
molecular weight, residual acetylation degree and chemical modifications [86]. 
The effect of these water-soluble chitosans on indices of oxidative stress in normal volunteers 
was reported for the first time in 2009 [86]. The authors demonstrated that chitosan treatment led to 
a decrease in plasma glucose and HDL-CH levels and atherogenic index [39]. A lowering effect on 
the oxidized to reduced albumin ratio and an increase in total plasma antioxidant activity (TPA) was 
also reported [37]. Since the oxidized albumin ratio represents a potentially useful marker of 
oxidative stress, some in vitro studies were carried out showing a significant decrease in albumin 
carbonyls and hydroperoxides in a time-dependent fashion, and also the reduction of two stable 
radicals in a dose- and time-dependent manner, after chitosan administration [86]. 
These results allow the conclusion that by lowering oxidative stress indices either in vitro or in 
vivo, chitosan acts as a direct antioxidant agent, which may be an additional benefit to plasma 
carbohydrate lowering and HDL level increase [86]. Furthermore, it can also inhibit serum albumin 
oxidation, for example, in diabetic patients who undergo hemodialysis, leading to a reduction of 
oxidative stress associated with uremia [86]. 
Chitosans may therefore be an alternative approach in the future of metabolic syndrome and 
T2DM management, as potent antioxidant agents [86]. 
4.7. Ginseng 
Ginseng is one of the most widely used natural compounds. Ginseng root has been used for over 
2000 years due to its health-promoting properties. Over the last few years, it has persistently been 
placed on the top ten of selling herbs in the United States [100,101]. 
The most commonly used Ginseng species are Panax ginseng (Asian ginseng) and Panax 
quinquefolius (American ginseng) [101,102]. In addition, ginseng derivatives may vary in chemical 
composition depending on the chosen plant extract, root age, growth location, harvest season and 
drying method. The ginseng species are all made up of ginsenosides, polysaccharides, peptides, 
polyacetylenic alcohol, and fatty acids [101,102]. 
Ginseng actions associated with the pharmacological targets are mainly due to ginsenosides, 
which belong to the steroidal saponin family [103]. Ginsenosides demonstrate an ability to target a 
myriad of tissues, producing an array of pharmacological responses although their exact mechanism 
in not well-known [103]. Different hypotheses regarding ginseng’s mechanisms of action have been 
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proposed: (1) ginseng may slow food digestion by a decrease in carbohydrate absorption rate into the 
portal circulation in liver [100,101]; (2) ginseng can either modify nitric oxide (NO)-mediated glucose 
transport or contribute to the modulation of the insulin secreted by NO mediation [100,101] and (3) 
ginseng may interfere in the inflammatory pathway in both insulin-dependent and insulin-
independent manners [62]. 
There are very few known ginseng adverse effects and the most common ones are nervousness 
and excitation, which may be reduced by prolonged use or dosage reduction [100,101]. 
4.8. Momordica charantia (Bitter Melon) 
Momordica charantia or bitter melon is widely cultivated in Asia, Africa, and South America 
[104,105]. The hypoglycemic action of the fresh juice or unripe fruit was reported after in vivo studies 
in animal experimental models and also human clinical trials. Bitter melon preparations orally 
administered have shown promising results in clinical trials involving T2DM patients [106]. 
4.9. Trigonella foenum graecum (Fenugreek) 
Trigonella foenum graecum has long been used for its anti-diabetic, anti-oxidant, and anti-
inflammatory properties [107]. The active compound is found in the non-fatted portion of the seed, 
which also contains saponins, flavonoids, lipids, vitamins and minerals. Moreover, literature reports 
the liver protective, obesity combating, hypoglycemic, anti-diabetic and cholesterol lowering 
properties of the seed [108,109]. In particular, the glucose- and lipid- lowering effects were also 
noticed in human studies[110]. At least 50% of the seed is composed of fiber which may be viewed 
as another possible mechanism of fenugreek’s action in T2DM patients, since it promoted a great 
reduction of both fasting plasma and post-prandial blood glucose levels [110]. The antidiabetic effects 
of the seeds are attributed to galactomannan which decreases insulin resistance and glucose 
resorption from the gastrointestinal tract; 4-hydroxyisoleucin (4-OH-Ile) which increases insulin 
secretion, diosgenin and trigonelline due improving β-cell regeneration [111]. 
4.10. Gymnema sylvestre (Gurmar) 
Gymnema sylvestre is a tropical plant native to the Indian forests and also a well-known 
Ayurvedic anti-sweet plant used in T2DM treatment [70]. It is an important fact that Gymnema 
sylvestre varies in its chemical composition depending on the geography: species from Vietnam are 
not equal to those in India. In 3T3-L1 adipocyte cells, gymnemosides produce a stimulating effect on 
2-NBDG uptake, thus being promising as lead molecules for novel anti-diabetic therapies [70]. 
Gymnema sylvestre is known as a “sugar blocker” [112]. In a T2DM clinical study, Gymnema 
sylvestre extract was administered daily along with oral antidiabetic drugs [113]. All patients showed 
an improvement on glycemic control and, when combining both therapies, it was possible to 
considerably reduce oral hypoglycemic drug dosage or even discontinue oral medication and 
maintain glycemic control with the Gymnema extract alone, as it has succeeded with five of these 
patients. 
4.11. Allium cepa and Allium sativum 
Both Allium cepa (onions) [114] and Allium sativum (garlic) [115] have shown a good performance 
as blood sugar lowering agents in several studies [116–118]. Volatile oils present in either raw onion 
or garlic cloves revealed a fasting glucose level lowering effect in diabetic animal models and 
humans. Sulfur-containing compounds—allyl propyl disulfide (APDS) in onions and diallyl 
disulfide (allicin) in garlic—seem to be the active constituents of these products. Since organosulfur 
compounds (OSCs) from plant extracts have shown antioxidant, blood glucose lowering, anti-
inflammatory and immunomodulatory actions, they may be considered as cardioprotective in T2DM. 
Garlic OSCs have the interesting feature of gasotransmitter H2S production and should be 
incorporated in the dietary regimen of type 2 diabetic individuals [52,119]. These active ingredients 
are able to reduce glycemia by competition against insulin for liver insulin-inactivating sites, thus 
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producing high levels of free insulin [52]. Sulfur compounds such as S-methylcysteine and flavonoids 
(e.g., quercetin) are the main responsible compounds for the glucose-lowering ability of Allium cepa. 
and also participate in the reduction of serum lipids, oxidative stress and lipid peroxidation, in 
parallel to an increased antioxidant activity and insulin secretion [119]. 
4.12. Pterocarpus marsupium and other Epicatechin-Containing Plants  
From the bark of Pterocarpus marsupium plants, used long ago by Indian people to manage 
diabetes, the flavonoid epicatechin may be extracted [120]. This compound acts in beta-cell damage 
prevention, as shown in rats. Additionally, studies performed in diabetic animal models with either 
epicatechin or a crude alcohol extract from P. marsupium have revealed their ability to regenerate 
pancreatic beta-cells with a preserved function [121]. Among the components of P. marsupium, 
epicatechin and catechin, which belong to flavan-3-ols family, are composed of glycosides and esters 
that may be responsible for their anti-diabetic action [122]. Similarly, both Camellia sinensis (green 
tea polyphenols) and Acacia cate-chu (Burma cutch) may be considered as flavan-3-ols enriched 
compounds. Cathecins such as epigallocathecin gallate have been proposed as new actives in 
nanoformulations for the management of diabetic retinopathy [123–126].  
4.13. Vaccinium myrtillus (Bilberry) 
The shrub Vaccinium myrtillus, also known as bilberry or European blueberry, typically grows in 
Europe and its leaves are increasingly used for diabetes treatment prior to marketed insulin 
availability [127]. However, the fruit has also beneficial properties attributed to the presence of 
Anthocyanoside, a compound that reduces fasting glucose, serum cholesterol and HbA1C in T2DM 
patients [128]. 
Several bioactive components (e.g., vitamins, phenolic acid and chlorogenic acid) which are 
increasingly incorporated in blueberry fruits, may contribute to a protective effect by (i) oxidative 
stress inhibition, (2) blood glucose metabolism control, (3) lipid profile improvement and (4) 
inflammatory cytokine lowering activity [73,128]. 
4.14. Atriplex halimus (Salt Bush) 
Atriplex halimus, commonly known as salt bush, is a plant endemic to Israel; its aqueous leaf 
extract has demonstrated to reduce blood and liver glucose levels [129]. In vivo studies performed 
with diabetic rats (sand rats) revealed the T2DM onset in the absence of the A. hamilus [130]. 
4.15. Aloe vera 
Aloe vera has long ago been recognized as a traditional therapy for diabetes management [131]. 
Orally administered aloe vera juice produced from the plant leaves (aloe vera gel) has shown promising 
results in reducing fasting glycemia and triglycerides in T2DM patients, either alone or combined 
with any conventional antidiabetic drug [132]. Aloe vera contains phytosterols that exhibit long-term 
glycemic control, being active against diabetes type II [133]. 
In addition, clinical trials undertaken with Aloe gel show that it may be a safe anti-
hyperglycemic and anti-hypercholesterolemic agent for T2DM patients presenting with 
hyperlipidemia [134,135]. 
5. Conclusions 
As diabetes mellitus is a metabolic disorder related to complex disturbances in carbohydrate, 
protein and fat metabolisms, interest remains to discover innovative and highly-effective glucose-
lowering agents, with minimal adverse effects and low toxicity. Currently available pharmacological 
options discussed in this review include sulphonylureas, thiazolidinediones, α-glucosidase 
inhibitors, sodium-glucose co-transporter type 2 inhibitors and dual SGLT1/SGLT2 agonists, 
glucagon-like peptide-1 amide (GLP-1) receptor agonists, dipeptidyl-peptidase-4 inhibitors, bile acid 
sequestrants, dopamine type 2 receptor agonists, amylin mimetics, mangiferin-berberine salt, β-
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tigogenin cellobioside, incretin-based therapies, TGR 5 agonists, β-cell acting compounds, small-
molecule insulin releasers, glucokinase activators, fatty Acid Receptor Agonists, imeglimin, 
adipokine-based treatments, selective peroxisome proliferator-activated receptor (PPAR) 
modulators, 11β-hydroxysteroid dehydrogenase 1 inhibitors, antiobesity drugs, 55P0110, 
antiosteoporotic trace minerals: Silicon and strontium, hybrid Molecules and Hybrid natural 
products, bis(α-furancarboxylato)oxovanadium (IV), LR Compounds: LR-9 and LR-74, 
insulinomimetic zinc (II) complexes with natural products, 4-(2,2-dimethyl-L-oxopropyl)benzoic 
acid, boronated nucleosides and nucleotides. Natural compounds such as diplacone and mimulone, 
ethanolic extract of Semecarpus anacardium (Linn.) bark, catalpol, apigenin-6-C-2”-O-α-L-
rhamnopyranosyl)-β-L-fucopyranoside, sophora japonica L., water-soluble chitosan, ginseng, 
Momordica charantia, Trigonella foenum graecum, Gymnema sylvestre, Allium cepa and Allium sativum, 
Pterocarpus marsupium and other Epicatechin-containing plants, Vaccinium myrtillus, Atriplex halimus 
and aloe vera, have also been considered as potential therapeutic approaches. Alongside drug 
research, a meticulous selection of the raw materials, animal models for in vivo experiments and also 
proper routes to administrate the testing compounds must be ensured. 
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